title: CDK6, a new target in MLL-driven leukemia.
abstract: In this issue of Blood, Placke et al identify the cell-cycle regulator CDK6 as a promising new target in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) and show that its downregulation or pharmacological inhibition leads to growth inhibition and differentiation of MLL-driven leukemic cells.
authors.affiliation: ALBERT EINSTEIN COLLEGE OF MEDICINE.
authors.forename: Iléana
authors.initials: I
authors.lastname: Antony-Debré
authors.affiliation: ALBERT EINSTEIN COLLEGE OF MEDICINE.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Steidl
mesh_terms: D000818:Animals; D051361:Cyclin-Dependent Kinase 6 / Q000378:metabolism*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*
chemical_list: D051788:Myeloid-Lymphoid Leukemia Protein; D051361:Cyclin-Dependent Kinase 6